CONTEXT: The incidence of multiple primary melanomas ranges from 1.3% to 8.0% in large retrospective reviews; however, the impact of certain risk factors is not understood. OBJECTIVES: To determine the incidence of multiple primary melanomas (MPM) from a prospective, single-institution, multidisciplinary database, and to describe the clinical and pathological characteristics and risk factors specific to these patients. DESIGN AND SETTING: Review of a prospectively maintained database at Memorial Sloan-Kettering Cancer Center in New York, NY. PATIENTS: A total of 4484 patients diagnosed with a first primary melanoma between January 1, 1996, and December 31, 2002. MAIN OUTCOME MEASURES: Incidence of and risk factors for MPM. RESULTS: Three hundred eighty-five patients (8.6%) had 2 or more primary melanomas, with an average of 2.3 melanomas per MPM patient. Seventy-eight percent had 2 primary melanomas. For 74% of patients, the initial melanoma was the thickest tumor. Fifty-nine percent presented with their second primary tumor within 1 year. Twenty-one percent of MPM patients had a positive family history of melanoma compared with only 12% of patients with a single primary melanoma (SPM) (P<.001). Thirty-eight percent of MPM patients had dysplastic nevi compared with 18% of SPM patients (P<.001). The estimated cumulative 5-year risk of a second primary tumor for the entire cohort was 11.4%, with almost half of that risk occurring within the first year. For patients with a positive family history or dysplastic nevi, the estimated 5-year risk of MPM was significantly higher at 19.1% and 23.7%, respectively. The most striking increase in incidence for the MPM population was seen for development of a third primary melanoma from the time of second primary melanoma, which was 15.6% at 1 year and 30.9% at 5 years. CONCLUSIONS: The incidence of MPM is increased in patients with a positive family history and/or dysplastic nevi. These patients should undergo intensive dermatologic screening and should consider genetic testing.
CONTEXT: The incidence of multiple primary melanomas ranges from 1.3% to 8.0% in large retrospective reviews; however, the impact of certain risk factors is not understood. OBJECTIVES: To determine the incidence of multiple primary melanomas (MPM) from a prospective, single-institution, multidisciplinary database, and to describe the clinical and pathological characteristics and risk factors specific to these patients. DESIGN AND SETTING: Review of a prospectively maintained database at Memorial Sloan-Kettering Cancer Center in New York, NY. PATIENTS: A total of 4484 patients diagnosed with a first primary melanoma between January 1, 1996, and December 31, 2002. MAIN OUTCOME MEASURES: Incidence of and risk factors for MPM. RESULTS: Three hundred eighty-five patients (8.6%) had 2 or more primary melanomas, with an average of 2.3 melanomas per MPM patient. Seventy-eight percent had 2 primary melanomas. For 74% of patients, the initial melanoma was the thickest tumor. Fifty-nine percent presented with their second primary tumor within 1 year. Twenty-one percent of MPM patients had a positive family history of melanoma compared with only 12% of patients with a single primary melanoma (SPM) (P<.001). Thirty-eight percent of MPM patients had dysplastic nevi compared with 18% of SPM patients (P<.001). The estimated cumulative 5-year risk of a second primary tumor for the entire cohort was 11.4%, with almost half of that risk occurring within the first year. For patients with a positive family history or dysplastic nevi, the estimated 5-year risk of MPM was significantly higher at 19.1% and 23.7%, respectively. The most striking increase in incidence for the MPM population was seen for development of a third primary melanoma from the time of second primary melanoma, which was 15.6% at 1 year and 30.9% at 5 years. CONCLUSIONS: The incidence of MPM is increased in patients with a positive family history and/or dysplastic nevi. These patients should undergo intensive dermatologic screening and should consider genetic testing.
Authors: David C Gibbs; Irene Orlow; Peter A Kanetsky; Li Luo; Anne Kricker; Bruce K Armstrong; Hoda Anton-Culver; Stephen B Gruber; Loraine D Marrett; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Terence Dwyer; Ajay Sharma; Emily La Pilla; Lynn From; Klaus J Busam; Anne E Cust; David W Ollila; Colin B Begg; Marianne Berwick; Nancy E Thomas Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-04-02 Impact factor: 4.254
Authors: Elena Losina; Rochelle P Walensky; Alan Geller; Frederick C Beddingfield; Lindsey L Wolf; Barbara A Gilchrest; Kenneth A Freedberg Journal: Arch Dermatol Date: 2007-01
Authors: Anne Kricker; Bruce K Armstrong; Chris Goumas; Melisa Litchfield; Colin B Begg; Amanda J Hummer; Loraine D Marrett; Beth Theis; Robert C Millikan; Nancy Thomas; Hoda Anton Culver; Richard P Gallagher; Terence Dwyer; Timothy R Rebbeck; Peter A Kanetsky; Klaus Busam; Lynn From; Urvi Mujumdar; Roberto Zanetti; Marianne Berwick Journal: Cancer Causes Control Date: 2007-01-06 Impact factor: 2.506
Authors: Giuseppe Palmieri; Maria Colombino; Milena Casula; Mario Budroni; Antonella Manca; Maria Cristina Sini; Amelia Lissia; Ignazio Stanganelli; Paolo A Ascierto; Antonio Cossu Journal: Melanoma Manag Date: 2015-05-18
Authors: Miriam Potrony; Celia Badenas; Paula Aguilera; Joan Anton Puig-Butille; Cristina Carrera; Josep Malvehy; Susana Puig Journal: Ann Transl Med Date: 2015-09
Authors: A W L Bayci; D A Baker; A E Somerset; O Turkoglu; Z Hothem; R E Callahan; R Mandal; B Han; T Bjorndahl; D Wishart; R Bahado-Singh; S F Graham; R Keidan Journal: Metabolomics Date: 2018-08-03 Impact factor: 4.290
Authors: June K Robinson; Jeffrey D Wayne; Mary C Martini; Brittney A Hultgren; Kimberly A Mallett; Rob Turrisi Journal: JAMA Dermatol Date: 2016-09-01 Impact factor: 10.282